messag provid updat model reflect chang estim
base comment manag lower revenu estim
zejula varubi subsequ year lower price target
tesaro chang price target reflect decreas revenu
estim zejula varubi revenu estim
decreas model zejula varubi sale
first take one might suggest sale product tsro especi zejula
mainten ovarian cancer live expect lower
outer year sale estim zejula varubi howev chang
outer year forecast sinc zejula launch share perhap
good competit erod demand messag want commun
fact think demand trend quit strong without guidanc number
outer year simpli robust product oncolog space gener
million first three quarter market appear quit good us fact sale
zejula first full year market june june may approach
million comparison sale first full year market septemb
septemb xtandi albeit prostat cancer time own
mediv mdvn ex-u
remind june conduct survey among gynecolog oncologist
oncologist treat ovarian cancer oc obtain real-world prescrib habit
data parpi usag key find survey
doctor prescrib zejula doctor prescrib zejula
broader label doctor indic parp inhibitor
least somewhat differ opinion data support hypothesi
zejula stand among parp inhibitor medic commun seem
congruent zejula least survey know limit appear
wide prescrib parp inhibitor conclus believ zejula may
captur biggest market share base initi trend survey coupl
earli sign prescript written recogn may chang follow label
chang may benefit compet parp olaparib azn rucaparib
broaden market ovarian cancer
furthermor tesaro broaden ovarian cancer market varieti trial
differ treatment line oc ovarian cancer compani expand front-
line indic posit ovarian cancer phase prima trial proof-of-
concept phase ovario trial combin bevacizumab phase first
trial combin tsro addit on-going trial recurr platinum-
respons oc includ quadra avanova well platinum-resist recurr
oc proc includ topacio opal
believ ovarian cancer market shift posit tsro favor
result trial expect compani face competit clovi
like receiv similar expand label affect view
investor wonder tsro trade premium current
enterpris valu tsro enterpris valu given
breadth tsro clinic trial ovarian breast cancer believ modest
premium even greater littl ascrib zejula breast
page analyst certif import disclosur
cancer io pipelin includ anti-lag program
even risk adjust basi
first market arguabl best-in-class tsro like see growth futur
year given expans pipelin tsro also receiv approv zejula
europ women recurr ovarian cancer regardless brca mutat biomark
statu advanc compani expans oc market tsro
believ ovarian cancer market repres peak opportun global
lower price target tesaro chang price target
reflect decreas revenu estim zejula varubi price target
base dcf analysi use unchang discount rate reflect
risk adjust alreadi made futur cash unchang termin growth rate
base manag commentari realist assumpt made
adjust tsro model slightli lower sale estim
niraparib zejula ovarian cancer base reiter guidanc
provid manag bring fy estim
consequ ep estim move
lower zejula varubi revenu estim outer year
adjust product revenu estim decreas
respect ep estim
decreas respect model profit
ep estim
valuat risk
valuat price target base forward sum-of-the-part dcf
analysi includ risk-adjust revenu rolapit zejula rolapit oral
formul chemotherapy-induc vomit includ revenu well risk-
adjust revenu iv version model profit tsro gener
ep valuat appli unchang discount rate reflect risk
adjust alreadi made futur cash flow unchang termin growth rate
risk risk rate price target includ limit tsro failur
gain regulatori approv rolapit certain geographi iv formul etc inabl
execut commerci rolapit lower-than-expect /ex-u
rolapit sale longer term key risk includ unfavor clinical/regulatori
outcom zejula ovarian cancer breast cancer
page analyst certif import disclosur
thousand except per-shar figur
niraparib oc
niraparib bc
niraparib nsclc
io portfolio tnbc risk-adjust
develop licens agreement
grant contract
good
goods-intang amort
mileston payment mrk/opko
acquir in-process research develop
incom loss oper
unreal loss gain secur
compani report guggenheim secur llc
page analyst certif import disclosur
